High fascin-1 expression in colorectal cancer identifies patients at high risk for early disease recurrence and associated mortality.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ metabolism
Carrier Proteins
/ metabolism
Colorectal Neoplasms
/ metabolism
Disease Progression
Female
Humans
Lymphatic Metastasis
Male
Microfilament Proteins
/ metabolism
Middle Aged
Neoplasm Recurrence, Local
/ metabolism
Neoplasm Staging
Prognosis
Survival Rate
Cancer stem cells
Colorectal cancer
Cytoskeleton
Fascin-1
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
01
04
2020
accepted:
26
01
2021
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Fascin is the main actin cross-linker protein that regulates adhesion dynamics and stabilizes cell protrusion, such as filopodia. In human cancer, fascin expression correlates with aggressive clinical features. This study aimed to determine the expression patterns of fascin-1 and assessed its prognostic significance in colorectal cancer. One hundred eleven specimens of patients with primary resectable colorectal cancer were examined via immunohistochemistry for the expression of fascin-1, and the results were correlated with clinicopathological characteristics and survival data. Fascin-1 staining displayed strong intensity in the cytoplasm of the colorectal cancer cells and endothelial cells of tumor blood vessels. Moderate to high fascin-1 expression was associated with progressive anatomic disease extent (p < 0.001), higher T classification (p = 0.007), the presence of lymph node (p < 0.001) and distant metastasis (p = 0.002), high grade tumors (p = 0.002) and vascular invasion (p < 0.001). Patients displaying moderate and high fascin-1 expression demonstrated a significantly worse 5-year overall survival [HR; 3.906, (95%CI) = 1.250-12.195] and significantly worse 3-year progression-free survival [HR; 3.448, (95%CI) = 1.401-8.475] independent of other clinicopathological characteristics. Besides, high fascin-1 expression in early-stage cancer only was associated with a dismal prognosis. High fascin-1 expression in colorectal cancer is an independent negative prognostic factor for survival, increasing the risk for disease recurrence or death almost by sevenfold. Fascin-1 expression could be potentially utilized to identify high-risk patients prone to metastasis already in early-stage disease.
Sections du résumé
BACKGROUND
BACKGROUND
Fascin is the main actin cross-linker protein that regulates adhesion dynamics and stabilizes cell protrusion, such as filopodia. In human cancer, fascin expression correlates with aggressive clinical features. This study aimed to determine the expression patterns of fascin-1 and assessed its prognostic significance in colorectal cancer.
METHODS
METHODS
One hundred eleven specimens of patients with primary resectable colorectal cancer were examined via immunohistochemistry for the expression of fascin-1, and the results were correlated with clinicopathological characteristics and survival data.
RESULTS
RESULTS
Fascin-1 staining displayed strong intensity in the cytoplasm of the colorectal cancer cells and endothelial cells of tumor blood vessels. Moderate to high fascin-1 expression was associated with progressive anatomic disease extent (p < 0.001), higher T classification (p = 0.007), the presence of lymph node (p < 0.001) and distant metastasis (p = 0.002), high grade tumors (p = 0.002) and vascular invasion (p < 0.001). Patients displaying moderate and high fascin-1 expression demonstrated a significantly worse 5-year overall survival [HR; 3.906, (95%CI) = 1.250-12.195] and significantly worse 3-year progression-free survival [HR; 3.448, (95%CI) = 1.401-8.475] independent of other clinicopathological characteristics. Besides, high fascin-1 expression in early-stage cancer only was associated with a dismal prognosis.
CONCLUSIONS
CONCLUSIONS
High fascin-1 expression in colorectal cancer is an independent negative prognostic factor for survival, increasing the risk for disease recurrence or death almost by sevenfold. Fascin-1 expression could be potentially utilized to identify high-risk patients prone to metastasis already in early-stage disease.
Identifiants
pubmed: 33579217
doi: 10.1186/s12885-021-07842-4
pii: 10.1186/s12885-021-07842-4
pmc: PMC7881491
doi:
Substances chimiques
Biomarkers, Tumor
0
Carrier Proteins
0
FSCN1 protein, human
0
Microfilament Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Commentaires et corrections
Type : ErratumIn
Références
Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol. 2007;18:460–6.
pubmed: 18023337
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.
pubmed: 19262571
Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou J, Burchell JM. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008;10:R52.
pubmed: 18541018
pmcid: 2481500
Marotta LL, Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev. 2009;19:44–50.
pubmed: 19167210
Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science. 2009;324:1670–3.
pubmed: 19556499
pmcid: 2873047
Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–9.
pubmed: 19737509
Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120:41–50.
pubmed: 20051635
pmcid: 2798700
Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103:382–90.
pubmed: 20606680
pmcid: 2920016
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.
pubmed: 12189386
pmcid: 12189386
Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108:1397–402.
pubmed: 21220315
pmcid: 3029760
Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18:43–73.
pubmed: 3597235
pmcid: 3597235
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
pubmed: 31912902
pmcid: 31912902
Condeelis J, Singer RH, Segall JE. The great escape: when cancer cells hijack the genes for chemotaxis and motility. Annu Rev Cell Dev Biol. 2005;21:695–718.
pubmed: 16212512
Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 2000;19(I-XI):193–383.
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8.
pubmed: 12778135
Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–92.
pubmed: 22000009
pmcid: 3261217
Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69.
pubmed: 16212495
Mogilner A, Rubinstein B. The physics of filopodial protrusion. Biophys J. 2005;89:782–95.
pubmed: 15879474
pmcid: 1366629
Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science. 2009;326:1208–12.
pubmed: 19965462
pmcid: 3677050
Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9:446–54.
pubmed: 18464790
Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol. 2006;174:863–75.
pubmed: 16966425
pmcid: 2064340
Claessens MM, Bathe M, Frey E, Bausch AR. Actin-binding proteins sensitively mediate F-actin bundle stiffness. Nat Mater. 2006;5:748–53.
pubmed: 16921360
Hashimoto Y, Kim DJ, Adams JC. The roles of fascins in health and disease. J Pathol. 2011;224:289–300.
pubmed: 21618240
Machesky LM, Li A. Fascin: Invasive filopodia promoting metastasis. Commun Integr Biol. 2010;3:263–70.
pubmed: 20714410
pmcid: 2918773
Tampakis A, Tampaki EC, Nonni A, Droeser R, Posabella A, Tsourouflis G, Kontzoglou K, Patsouris E, von Flue M, Kouraklis G. Nectin-1 expression in colorectal Cancer: is there a Group of Patients with high risk for early disease recurrence? Oncology. 2019;96:318–25.
pubmed: 30917374
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005;2:416–22.
pubmed: 16482653
Tampakis A, Tampaki E, Nonni A, Patsouris E, von Flue M, Kontzoglou K, Kouraklis G. L1CAM expression in colorectal cancer identifies patients prone to metastasis already in early-stage disease. Ann Oncol. 2019;30(Suppl 4):iv60.
Tampakis A, Tampaki EC, Nonni A, Tsourouflis G, Posabella A, Patsouris E, Kontzoglou K, von Flue M, Nikiteas N, Kouraklis G. L1CAM expression in colorectal cancer identifies a high-risk group of patients with dismal prognosis already in early-stage disease. Acta Oncol. 2020;59:55–9.
pubmed: 31532272
Tan VY, Lewis SJ, Adams JC, Martin RM. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 2013;11:52.
pubmed: 23442983
pmcid: 3635876
Oh SY, Kim YB, Suh KW, Paek OJ, Moon HY. Prognostic impact of fascin-1 expression is more significant in advanced colorectal cancer. J Surg Res. 2012;172:102–8.
pubmed: 20851411
Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer. 2007;96:1118–26.
pubmed: 17375048
pmcid: 2360113
Chan C, Jankova L, Fung CL, Clarke C, Robertson G, Chapuis PH, Bokey L, Lin BP, Dent OF, Clarke S. Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Pathol. 2010;34:656–66.
pubmed: 20410808
Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer. 2006;6:241.
pubmed: 17029629
pmcid: 1615879
Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 2005;37:1787–804.
pubmed: 16002322
Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis. 2000;18:83–8.
pubmed: 11206843
Jayo A, Malboubi M, Antoku S, Chang W, Ortiz-Zapater E, Groen C, Pfisterer K, Tootle T, Charras G, Gundersen GG, Parsons M. Fascin regulates nuclear movement and deformation in migrating cells. Dev Cell. 2016;38:371–83.
pubmed: 27554857
pmcid: 4997957
Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M, Adams JC. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol. 2003;162:69–80.
pubmed: 12507891
pmcid: 1851132
Brieger J, Duesterhoeft A, Brochhausen C, Gosepath J, Kirkpatrick CJ, Mann WJ. Recurrence of pleomorphic adenoma of the parotid gland--predictive value of cadherin-11 and fascin. APMIS. 2008;116:1050–7.
pubmed: 19133007
Zou J, Yang H, Chen F, Zhao H, Lin P, Zhang J, Ye H, Wang L, Liu S. Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev. 2010;19:11–7.
pubmed: 19741544
Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Lae M, Louvard D, Ben-Ze’ev A, Robine S. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res. 2007;67:6844–53.
pubmed: 17638895
Huang FK, Han S, Xing B, Huang J, Liu B, Bordeleau F, Reinhart-King CA, Zhang JJ, Huang XY. Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization. Nat Commun. 2015;6:7465.
pubmed: 26081695
Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY. Migrastatin analogues target fascin to block tumour metastasis. Nature. 2010;464:1062–6.
pubmed: 20393565
pmcid: 2857318
Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology. 2004;67:262–70.
pubmed: 15557788
Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006;12:1533–9.
pubmed: 16533778
Boland CR, Goel A. Prognostic subgroups among patients with stage II Colon Cancer. N Engl J Med. 2016;374:277–8.
pubmed: 26789877
pmcid: 4852473
Marshall JL. Risk assessment in stage II colorectal cancer. Oncology (Williston Park). 2010;24:9–13.
Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408–19.
pubmed: 15199089